middle.news
How Syntara’s Amsulostat Fast Track Could Transform Myelofibrosis Treatment
2:48am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
How Syntara’s Amsulostat Fast Track Could Transform Myelofibrosis Treatment
2:48am on Saturday 30th of August, 2025 AEST
Key Points
Loss narrowed to $7.9 million from $15.1 million in prior year
Amsulostat granted FDA Fast Track and WHO International Non-Proprietary Name
Completed $20 million capital raising in 2024-25 to fund clinical programs
Sale of mannitol respiratory business classified as discontinued operations
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Syntara (ASX:SNT)
OPEN ARTICLE